Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.

病毒学 不利影响 安慰剂 血清转化 临床试验 效价 随机对照试验 耐受性 佐剂 内科学 免疫系统 严重急性呼吸综合征冠状病毒2型(SARS-CoV-2) 抗体效价 中和抗体
作者
David Hillus,Tatjana Schwarz,Pinkus Tober-Lau,Kanika Vanshylla,Hana Hastor,Charlotte Thibeault,Stefanie Jentzsch,Elisa T Helbig,Lena J Lippert,Patricia Tscheak,Marie Luisa Schmidt,Johanna Riege,André Solarek,Christof von Kalle,Chantip Dang-Heine,Henning Gruell,Piotr Kopankiewicz,Norbert Suttorp,Christian Drosten,Harald Bias,Joachim Seybold,Florian Klein,Florian Kurth,Victor M. Corman,Leif E. Sander
出处
期刊:The Lancet Respiratory Medicine 卷期号:9 (11): 1255-1265 被引量:68
标识
DOI:10.1016/s2213-2600(21)00357-x
摘要

Summary Background Heterologous vaccine regimens have been widely discussed as a way to mitigate intermittent supply shortages and to improve immunogenicity and safety of COVID-19 vaccines. We aimed to assess the reactogenicity and immunogenicity of heterologous immunisations with ChAdOx1 nCov-19 (AstraZeneca, Cambridge, UK) and BNT162b2 (Pfizer-BioNtech, Mainz, Germany) compared with homologous BNT162b2 and ChAdOx1 nCov-19 immunisation. Methods This is an interim analysis of a prospective observational cohort study enrolling health-care workers in Berlin (Germany) who received either homologous ChAdOx1 nCov-19 or heterologous ChAdOx1 nCov-19–BNT162b2 vaccination with a 10–12-week vaccine interval or homologous BNT162b2 vaccination with a 3-week vaccine interval. We assessed reactogenicity after the first and second vaccination by use of electronic questionnaires on days 1, 3, 5, and 7. Immunogenicity was measured by the presence of SARS-CoV-2-specific antibodies (full spike-IgG, S1-IgG, and RBD-IgG), by an RBD–ACE2 binding inhibition assay (surrogate SARS-CoV-2 virus neutralisation test), a pseudovirus neutralisation assay against two variants of concerns (alpha [B.1.1.7] and beta [B.1.351]), and anti-S1-IgG avidity. T-cell reactivity was measured by IFN-γ release assay. Findings Between Dec 27, 2020, and June 14, 2021, 380 participants were enrolled in the study, with 174 receiving homologous BNT162b2 vaccination, 38 receiving homologous ChAdOx1 nCov-19 vaccination, and 104 receiving ChAdOx1 nCov-19–BNT162b2 vaccination. Systemic symptoms were reported by 103 (65%, 95% CI 57·1–71·8) of 159 recipients of homologous BNT162b2, 14 (39%, 24·8–55·1) of 36 recipients of homologous ChAdOx1 nCov-19, and 51 (49%, 39·6–58·5) of 104 recipients of ChAdOx1 nCov-19–BNT162b2 after the booster immunisation. Median anti-RBD IgG levels 3 weeks after boost immunisation were 5·4 signal to cutoff ratio (S/co; IQR 4·8–5·9) in recipients of homologous BNT162b2, 4·9 S/co (4·3–5·6) in recipients of homologous ChAdOx1 nCov-19, and 5·6 S/co (5·1–6·1) in recipients of ChAdOx1 nCov-19– BNT162b2. Geometric mean of 50% inhibitory dose against alpha and beta variants were highest in recipients of ChAdOx1 nCov-19–BNT162b2 (956·6, 95% CI 835·6–1095, against alpha and 417·1, 349·3–498·2, against beta) compared with those in recipients of homologous ChAdOx1 nCov-19 (212·5, 131·2–344·4, against alpha and 48·5, 28·4–82·8, against beta; both p Interpretation The heterologous ChAdOx1 nCov-19–BNT162b2 immunisation with 10–12-week interval, recommended in Germany, is well tolerated and improves immunogenicity compared with homologous ChAdOx1 nCov-19 vaccination with 10–12-week interval and BNT162b2 vaccination with 3-week interval. Heterologous prime-boost immunisation strategies for COVID-19 might be generally applicable. Funding Forschungsnetzwerk der Universitatsmedizin zu COVID-19, the German Ministry of Education and Research, Zalando SE.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wanmiao12完成签到,获得积分10
1秒前
yu发布了新的文献求助10
2秒前
mmmmm完成签到,获得积分10
3秒前
洁净白容完成签到,获得积分10
3秒前
大个应助孟孟采纳,获得10
3秒前
小镇的废物完成签到,获得积分10
3秒前
柴郡喵完成签到,获得积分10
4秒前
SYLH应助小熊采纳,获得10
5秒前
妹妹发布了新的文献求助10
5秒前
5秒前
赘婿应助我必定发nature采纳,获得20
6秒前
Ava应助kofbird采纳,获得50
7秒前
zz完成签到,获得积分10
7秒前
星辰大海应助ybwei2008_163采纳,获得10
7秒前
9秒前
9秒前
QJYKKK完成签到,获得积分10
9秒前
composite66完成签到,获得积分10
9秒前
ccchao发布了新的文献求助30
10秒前
充电宝应助十三采纳,获得10
10秒前
大个应助橙橙橙采纳,获得10
10秒前
Dandanhuang完成签到,获得积分10
10秒前
FashionBoy应助孟孟采纳,获得30
12秒前
畅快的刚完成签到,获得积分10
14秒前
14秒前
xxxx完成签到,获得积分10
14秒前
vain发布了新的文献求助10
14秒前
李健应助芒果小鹌鹑采纳,获得10
14秒前
cc完成签到,获得积分10
15秒前
这个名字是不是独一无二完成签到,获得积分10
15秒前
颗粒完成签到,获得积分10
16秒前
16秒前
javeeen完成签到,获得积分10
17秒前
应俊完成签到 ,获得积分10
17秒前
1234完成签到 ,获得积分10
18秒前
轻松元柏完成签到,获得积分10
19秒前
WN发布了新的文献求助10
19秒前
19秒前
我必定发nature给我必定发nature的求助进行了留言
20秒前
组织因子发布了新的文献求助10
20秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038569
求助须知:如何正确求助?哪些是违规求助? 3576279
关于积分的说明 11374944
捐赠科研通 3305979
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815048